178
Participants
Start Date
December 31, 2010
Primary Completion Date
November 30, 2013
Study Completion Date
January 31, 2014
PX-866 (SCCHN)
PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Cetuximab (SCCHN)
Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
PX-866 (CRC)
PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
Cetuximab (CRC)
Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
University of Pennsylvania, Philadelphia
George Washington University - Medical Faculty Associates, Washington D.C.
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Specialists, PC, Fairfax
Peninsula Cancer Institute, Newport News
Virginia Oncology Associates, Newport News
Oncology and Hematology Associates of Southwest Virginia, Roanoke
MUSC Hollings Cancer Center, Charleston
Peachtree Hematology-Oncology Consultants, Atlanta
Integrated Community Oncology Network, Jacksonville
Advanced Medical Specialties, Miami
Pasco Pinellas Cancer Center, New Port Richey
Birmingham Hematology and Oncology Assocs., Birmingham
University of Alabama Birmingham, Birmingham
Karmanos Cancer Institute, Detroit
Saint Louis Cancer Care LLP, Bridgeton
Mary Crowley Cancer Center, Dallas
Texas Oncology - Baylor Charles A. Sammons, Dallas
Texas Oncology - Fort Worth, Fort Worth
Texas Oncology - Seton Williamson, Round Rock
University of Colorado Denver, Aurora
Rocky Mountain Cancer Centers, Denver
Eastern Colorado Health Care System - (Denver VA), Denver
Comprehensive Cancer Centers of Nevada, Las Vegas
Southwest Cancer Care, Escondido
Ventura County Hematology Oncology Specialists, Oxnard
Monterey Bay Oncology, Monterey
Northwest Cancer Specialists, P.C., Tualatin
Medical Oncology Associates, Spokane
Columbia Basin Hematology and Oncology, Kennewick
Tufts Medical Center, Boston
Cross Cancer Institute, Edmonton
British Columbia Cancer Agency - Vancouver Centre, Vancouver
Royal Victoria Regional Health Centre, Barrie
Northeast Cancer Centre of Health Sciences North, Greater Sudbury
London Regional Cancer Program, London
Thunder Bay Regional Health Sciences Centre, Thunder Bay
Hôpital Charles-LeMoyne, Greenfield Park
Cité de la Santé de Laval, Laval
Maisonneuve-Rosemont Hospital Research Centre, Montreal
Lead Sponsor
Cascadian Therapeutics Inc.
INDUSTRY